Jim Dente of Advanced Pharmacy Solutions emphasizes the growing role of automation, artificial intelligence, and patient-centric business models in streamlining operations, improving patient care, and addressing industry challenges such as staff burnout and medication errors.
mRNA-1345 (mRESVIA; Moderna) has the potential to significantly transform the RSV disease state in 2025, according to data analysts.
Severe alcohol-associated hepatitis has limited effective pharmacological therapies, emphasizing the need for treatment options.
Posttraumatic stress disorder is found to be associated with coronary artery disease, hypertension, and heart failure.
The findings suggest that patients with alopecia areata (AA) who also have asthma may benefit from increased clinical monitoring and earlier intervention.
Patients with methotrexate (MTX)-induced acute kidney injury treated with glucarpidase were 2.70-times more likely to have kidney recovery and recover faster.
The approach favors administration of frequent low-dose chemotherapy to reduce toxicities and optimize outcomes.
Building on a previous report that revealed corrupt business practices among the big 3 PBMs, a second interim report finds that PBMs heightened prices for important specialty generic drugs to increase their profit margins.
New data shows that, in high-risk patients with advanced cutaneous squamous cell carcinoma, cemiplimab reduces the risk of disease recurrence and death.
These drugs are set to revolutionize their respective disease states in 2025.
The pharmaceutical industry is facing a critical talent shortage caused by fewer students entering the field, burnout and a lack of stability. We offer ways to combat the shortage.
Patients with rheumatoid arthritis and higher body mass index (BMI) showed poorer clinical response to non-tumor necrosis factor (TNF)-targeted treatments.
Wildfire smoke carries toxic compounds that can trigger respiratory inflammation and cause cellular damage.
Pharmacists should prioritize the needs of the patient in front of them and determine what matters most in each specific situation.
Women living in rural are more likely to report experiencing psychological and somatic menopause symptoms compared with those in urban and suburban areas.
Successfully integrating biosimilars into practices requires careful planning and execution, as they impact virtually all aspects of a practice.
Brentuximab vedotin is approved for treatment of adult and pediatric with classical Hodgkin lymphoma in combination with chemotherapy.
Dyslipidemia is a condition in which there are abnormal levels of lipids in the blood stream, including high levels of low-density lipoprotein cholesterol, low levels of high-density lipoprotein cholesterol, and/or high levels of triglycerides.
According to the investigators, BBO-8520 represents a first-in-class approach to treating patients with previously treated KRASG12C-mutated metastatic non-small cell lung cancer (NSCLC).
A new indication for the antibody-drug conjugate expands the future clinical potential of the treatment in patients with the rare breast cancer.
Datopotamab deruxtecan was also granted breakthrough therapy designation in December 2024.
Managing comorbidities, ensuring proper dosing, and treating IVIG-related adverse events are areas where pharmacists play a large role.
The new Medicare cap limits out-of-pocket drug costs to $2000 annually.
Pharmacy Times interviews Jennifer Clements, a clinical professor and the director of pharmacy education at the University of South Carolina, about glucagon-like peptide-1 receptors for diabetes treatment.
Hokkaido scallop oil plasmalogen and Apoaequorin have both been posited to improve brain health.
If approved, nipocalimab can treat antibody positive individuals with generalized myasthenia gravis.
The Kidney Disease: Improving Global Outcomes guidelines can provide pharmacists with approaches to minimizing chronic kidney disease progression and complications.
Virtual appointments were also an accessible alternative to in-person visits for patients who face obstacles accessing asthma care.
The proposed age restrictions on dietary supplements would limit consumer access to safe products.
The designation was supported by data from the phase 2, open-label, randomized, multi-center ARTEMIS-002 clinical trial, which assessed the safety and efficacy of GSK’227.
